Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Behr

Showing results (221-230 of 263) with videos related to

Pageof 27
Sort By:
Cancer Research|April 15, 1996
Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumorsT M Behr, R M Sharkey, M I Juweid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 1995
Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancerT M Behr, W S Becker, H J Bair, et al.
International Journal of Cancer|August 4, 1998
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacyT M Behr, S Memtsoudis, R M Sharkey, et al.
Genes and Immunity|May 9, 2014
Contribution of increased ISG15, ISGylation and deregulated type I IFN signaling in Usp18 mutant mice during the course of bacterial infectionsS M Dauphinee, E Richer, M M Eva, et al.
European Journal of Immunology|March 19, 2024
Intestinal tissue-resident memory T cells maintain distinct identity from circulating memory T cells after in vitro restimulationAmmarina Beumer-Chuwonpad, Felix M Behr, Floris P J van Alphen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignanciesT M Behr, B Wörmann, M Gramatzki, et al.
Cancer|March 6, 2002
Radioimmunotherapy of small-volume disease of metastatic colorectal cancerThomas M Behr, Torsten Liersch, Lutz Greiner-Bechert, et al.
Science Immunology|December 16, 2018
<b>T</b> <sub></sub> <b>maintenance is regulated by tissue damage via P2RX7</b>Regina Stark, Thomas H Wesselink, Felix M Behr, et al.
Cancer|December 24, 1997
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetryT M Behr, R M Sharkey, G Sgouros, et al.
Cancer Research|June 11, 1999
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer modelT M Behr, M Béhé, M G Stabin, et al.
Pageof 27

Showing results (221-230 of 263) with videos related to

Sort By:
Pageof 27
Cancer Research|April 15, 1996
Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumorsT M Behr, R M Sharkey, M I Juweid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 1995
Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancerT M Behr, W S Becker, H J Bair, et al.
International Journal of Cancer|August 4, 1998
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacyT M Behr, S Memtsoudis, R M Sharkey, et al.
Genes and Immunity|May 9, 2014
Contribution of increased ISG15, ISGylation and deregulated type I IFN signaling in Usp18 mutant mice during the course of bacterial infectionsS M Dauphinee, E Richer, M M Eva, et al.
European Journal of Immunology|March 19, 2024
Intestinal tissue-resident memory T cells maintain distinct identity from circulating memory T cells after in vitro restimulationAmmarina Beumer-Chuwonpad, Felix M Behr, Floris P J van Alphen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignanciesT M Behr, B Wörmann, M Gramatzki, et al.
Cancer|March 6, 2002
Radioimmunotherapy of small-volume disease of metastatic colorectal cancerThomas M Behr, Torsten Liersch, Lutz Greiner-Bechert, et al.
Science Immunology|December 16, 2018
<b>T</b> <sub></sub> <b>maintenance is regulated by tissue damage via P2RX7</b>Regina Stark, Thomas H Wesselink, Felix M Behr, et al.
Cancer|December 24, 1997
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetryT M Behr, R M Sharkey, G Sgouros, et al.
Cancer Research|June 11, 1999
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer modelT M Behr, M Béhé, M G Stabin, et al.
Pageof 27